FDA Safety Review on Cardiovascular Risks for Diabetics from Olmesartan: AttorneyOne Monitor and Kee
On June 24, the FDA communicated that there is no clear evidence of increased cardiovascular risks associated with use of Olmesartan in diabetic patients. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) July 01, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Olmesartan. The FDA issued a safety communication on June 24, stating that after completion of its safety review there is no cle
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Related Documents in PR Web
- Webinar to Focus on the Role of Patient Engagement Strategies in Promoting Population Health Managem
- High Alert for South Florida Bars - Jury Finds Bar Guilty of Over-Serving Patron to the Tune of $11M
- Attorneys Peggy Hoyt and Randy Bryan Named Featured Speakers at Planning for the Generations Symposi
Categories
- Articles 313
- Bankruptcy 44
- Business 135
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 57
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 609
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4